Sophia Genetics SA (NASDAQ:SOPH) — Market Cap & Net Worth
Market Cap & Net Worth: Sophia Genetics SA (SOPH)
Sophia Genetics SA (NASDAQ:SOPH) has a market capitalization of $321.60 Million ($321.60 Million) as of May 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14672 globally and #3300 in its home market, demonstrating a 9.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sophia Genetics SA's stock price $5.32 by its total outstanding shares 67847058 (67.85 Million). Analyse Sophia Genetics SA operating cash flow efficiency to see how efficiently the company converts income to cash.
Sophia Genetics SA Market Cap History: 2021 to 2026
Sophia Genetics SA's market capitalization history from 2021 to 2026. Data shows change from $956.64 Million to $360.95 Million (-21.36% CAGR).
Index Memberships
Sophia Genetics SA is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #394 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1406 of 3165 |
Weight: Sophia Genetics SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sophia Genetics SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sophia Genetics SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.20x
Sophia Genetics SA's market cap is 3.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $956.64 Million | $40.45 Million | -$73.67 Million | 23.65x | N/A |
| 2022 | $139.76 Million | $47.56 Million | -$87.45 Million | 2.94x | N/A |
| 2023 | $319.56 Million | $62.37 Million | -$78.98 Million | 5.12x | N/A |
| 2024 | $208.29 Million | $65.17 Million | -$62.49 Million | 3.20x | N/A |
Competitor Companies of SOPH by Market Capitalization
Companies near Sophia Genetics SA in the global market cap rankings as of May 3, 2026.
Key companies related to Sophia Genetics SA by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #926 globally with a market cap of $28.21 Billion USD.
- Pro Medicus Ltd (AU:PME): Ranked #2225 globally with a market cap of $10.06 Billion USD ( AU$14.22 Billion AUD).
- Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM): Ranked #2339 globally with a market cap of $9.34 Billion USD.
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2447 globally with a market cap of $8.82 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #926 | Veeva Systems Inc Class A | NYSE:VEEV | $28.21 Billion | $171.60 |
| #2225 | Pro Medicus Ltd | AU:PME | $10.06 Billion | AU$136.16 |
| #2339 | Tempus AI, Inc. Class A Common Stock | NASDAQ:TEM | $9.34 Billion | $55.00 |
| #2447 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $8.82 Billion | $52.58 |
Sophia Genetics SA Historical Marketcap From 2021 to 2026
Between 2021 and today, Sophia Genetics SA's market cap moved from $956.64 Million to $ 360.95 Million, with a yearly change of -21.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $360.95 Million | +13.92% |
| 2025 | $316.85 Million | +52.12% |
| 2024 | $208.29 Million | -34.82% |
| 2023 | $319.56 Million | +128.64% |
| 2022 | $139.76 Million | -85.39% |
| 2021 | $956.64 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Sophia Genetics SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $321.60 Million USD |
| MoneyControl | $321.60 Million USD |
| MarketWatch | $321.60 Million USD |
| marketcap.company | $321.60 Million USD |
| Reuters | $321.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sophia Genetics SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutic… Read more